Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :


By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :


Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Nash Pharma to Present Fatty Liver Disease Data in London

Stockhouse Editorial
0 Comments| February 1, 2019

Nash Pharmaceuticals , a wholly-owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH, OTCQB: BTHCD, Forum), stated this week that it will be presenting its pre-clinical data on its non-alcoholic steatohepatitis research program at the 2nd Global NASH Congress in London, U.K., February 25th & 26th, 2019.

For more, click here.

The Company recently made news with the announcement that in a recently completed study, its lead compound for non-alcoholic steatohepatitis (NASH) NP-160 showed an 84% reduction of fibrosis by additional lead compound In second pre-clinical study for non-alcoholic fatty liver disease. Phase II of clinical trials look to establish human efficacy.

FULL DISCLOSURE: Breathtec Biomedical Inc. is a client of Stockhouse Publishing.

Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Metals & Mining

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.